BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 19225113)

  • 21. Insights into the All-trans-Retinoic Acid and Arsenic Trioxide Combination Treatment for Acute Promyelocytic Leukemia: A Meta-Analysis.
    Ma H; Yang J
    Acta Haematol; 2015; 134(2):101-8. PubMed ID: 25925330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
    Estey E; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovsek S; Jones D; Kantarjian H
    Blood; 2006 May; 107(9):3469-73. PubMed ID: 16373661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.
    Shen ZX; Shi ZZ; Fang J; Gu BW; Li JM; Zhu YM; Shi JY; Zheng PZ; Yan H; Liu YF; Chen Y; Shen Y; Wu W; Tang W; Waxman S; De Thé H; Wang ZY; Chen SJ; Chen Z
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5328-35. PubMed ID: 15044693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.
    Lou Y; Ma Y; Suo S; Ni W; Wang Y; Pan H; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Wei J; Mao L; Jin J
    Leuk Res; 2015 Sep; 39(9):938-44. PubMed ID: 26183877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
    Dai CW; Zhang GS; Shen JK; Zheng WL; Pei MF; Xu YX; Cao YX; Yi Y; Yang JJ; Peng HL; Zhong HY; Li RJ
    Acta Haematol; 2009; 121(1):1-8. PubMed ID: 19246888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute promyelocytic leukemia: recent advances in diagnosis and management.
    Lo-Coco F; Ammatuna E; Montesinos P; Sanz MA
    Semin Oncol; 2008 Aug; 35(4):401-9. PubMed ID: 18692690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China.
    Zhang L; Zhu X; Zou Y; Chen Y; Chen X
    Int J Hematol; 2011 Feb; 93(2):199-205. PubMed ID: 21287409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
    Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z
    Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
    Ghavamzadeh A; Alimoghaddam K; Ghaffari SH; Rostami S; Jahani M; Hosseini R; Mossavi A; Baybordi E; Khodabadeh A; Iravani M; Bahar B; Mortazavi Y; Totonchi M; Aghdami N
    Ann Oncol; 2006 Jan; 17(1):131-4. PubMed ID: 16227315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
    Wang H; Chen XY; Wang BS; Rong ZX; Qi H; Chen HZ
    Leuk Res; 2011 Sep; 35(9):1170-7. PubMed ID: 21774985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience.
    Wang H; Hao L; Wang X; Li J; Wu Q; Bian S
    Int J Hematol; 2010 Jun; 91(5):820-5. PubMed ID: 20461563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treating low- and intermediate-risk acute promyelocytic leukemia with and without chemotherapy: A comparison in a tertiary care center.
    Saxena M; Madabhavi IV; Patel A; Panchal H; Anand A
    J Cancer Res Ther; 2023; 19(5):1371-1378. PubMed ID: 37787311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What is the role of arsenic in newly diagnosed APL?
    Tallman MS
    Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The clinical efficacy of all-trans retinoic acid plus arsenic trioxide in 177 newly diagnosed acute promyelocytic leukemia patients].
    Lu Y; Li F; Mu Q; Meng H; Qian W; Tong H; Mai W; Pei R; Yu M; Zhao X; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2015 May; 36(5):372-7. PubMed ID: 26031521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
    Lazo G; Kantarjian H; Estey E; Thomas D; O'Brien S; Cortes J
    Cancer; 2003 May; 97(9):2218-24. PubMed ID: 12712474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy.
    Dombret H; Fenaux P; Soignet SL; Tallman MS
    Semin Hematol; 2002 Apr; 39(2 Suppl 1):8-13. PubMed ID: 12012316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival.
    Chen Y; Gu L; Zhou C; Wu X; Gao J; Li Q; Zhu Y; Jia C; Ma Z
    Int J Hematol; 2010 May; 91(4):708-10. PubMed ID: 20405253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
    Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
    Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
    Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
    J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.
    Tomita A; Kiyoi H; Naoe T
    Int J Hematol; 2013 Jun; 97(6):717-25. PubMed ID: 23670176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.